Epidemics and pandemics

  • EbolaImproved protective suit for Ebola caregivers

    An advanced protective suit for health care workers who treat Ebola patients, devised by a Johns Hopkins University team, is one of the first five awardees in a federal funding contest aimed at quickly devising new tools to combat the deadly disease. The JHU prototype is designed to do a better job than current garments in keeping health care workers from coming in contact with Ebola patients’ contagious body fluids, both during treatment and while removing a soiled suit. In addition, it is expected to keep the wearer cooler — an important benefit in hot, humid regions such as West Africa.

  • Public healthPreventing animal-borne diseases from affecting humans

    Roughly 75 percent of newly emerging diseases are zoonotic, which means that they can spread from animals to humans. Incredibly damaging, these diseases usually wreak havoc on humans, who rarely have natural defenses to protect them against such strains. About 2.7 million people die each year from zoonotic diseases. It is estimated that between 1997 and 2009, the cost of dealing with and treating these types of diseases around the world amounted roughly $80 billion. Scientists hope that by connecting human medical and veterinary science, and by organizing and establishing different medical professionals along a spectrum of disease detection, it would be possible to thwart the outbreak of another zoonotic disease.

  • Infectious diseaseThe growing economic cost of infectious diseases

    Emerging pandemic disease outbreaks such as Ebola increasingly threaten global public health and world economies, scientists say. We can expect five new such diseases each year, into the future. We should also expect them to spread. The tropical disease dengue fever, for example, has made its way to Florida and Texas, seemingly to stay. Five new such diseases expected each year; strategies to reduce climate change adaptable to infectious diseases. Economists, disease ecologists, and others collaborated on an in-depth economic analysis of strategies to address pandemic threats in a proactive way — rather than a reactive response to a crisis.

  • EbolaTexas Ebola task force calls for revamping state’s preparations for epidemics

    The Texas Task Force on Infectious Disease Preparedness and Responsehas called for the establishment of two specialized Ebola treatment centers in Texas, and for new methods to monitor vulnerable health care workers, especially those returning from West Africa.The state acknowledges that it alone is unable to handle an infectious disease outbreak like Ebola. The task force wants federal health and disease authorities to provide actionable information during disease outbreaks.

  • TECHEXPO - Exclusive Security-Cleared Hiring Events - Register Now!
    view counter
  • Public healthWorld can be separated into seven regions for vectored human diseases

    Researchers have for the first time mapped human disease-causing pathogens, dividing the world into a number of regions where similar diseases occur. The findings show that the world can be separated into seven regions for vectored human diseases — diseases which are spread by pests, like mosquito-borne malaria — and five regions for non-vectored diseases, like cholera.

  • EbolaWorld's response to Ebola slow, inconsistent, inadequate: Médecins sans Frontières

    The NGO Médecins sans Frontières (MSF) has harshly criticized the international community for its slow and inconsistent response to the Ebola crisis in West Africa. MSF says the world’s response risks creating “a double failure” because ill-equipped locals in Sierra Leone, Liberia, and Guinea have been left to run hospitals and treatment centers. MSF international president, Dr. Joanne Liu, said it was “extremely disappointing that states with biological-disaster response capacities have chosen not to deploy them.”

  • EpidemicsSatellites help assess risk of epidemics

    Changes in the environment, global trade, and travel are all factors in the ever-increasing numbers and movement of pests. Identifying and predicting the distribution of existing local species as well as the spread of new exotic ones are essential in assessing the risk of potential epidemics. Researchers have developed Vecmap — an all-encompassing software and services package including a smartphone app for field studies with a time and location information system, all linked to an online database. The database pools satellite information with results from field research, and satnav adds location information. The new approach greatly reduces the complexity of tracking species compared to traditional methods.

  • EbolaPortable, fast Ebola test kit in trials in Guinea

    Scientists say that early diagnosis is key to surviving Ebola once a person has been infected. Roughly 50 percent of those known to be infected with Ebola have died, but scientists hope to reduce the number as a new test designed to diagnose the Ebola virus in humans in under fifteen minutes will be tried out at a treatment center in Conakry, Guinea. The test is six times faster than tests currently used in West Africa.The mobile testing device is one of six projects jointly funded by Wellcome and the U.K.’s Department for International Development under the 6.5 million pounds Research for Health in Humanitarian Crises initiative.

  • EbolaSubjects produce immune response, develop antibodies in Ebola vaccine test

    All twenty research subjects recruited by the University of Maryland School of Medicine in partnership with the National Institute of Health (NIH) to test an experimental Ebola vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with drug maker, GlaxoSmithKline, have produced an immune response and developed anti-Ebola antibodies. Half of the research participants were initially injected with ten billion particles of a chimpanzee cold virus modified to resemble Ebola, while the other half received a dose with ten times as many particles.

  • EbolaNIAID/GSK experimental Ebola vaccine appears safe, prompts immune response

    An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all twenty healthy adults who received it in a phase 1 clinical trial conducted by researchers from the National Institutes of Health. The results from the NIH Phase 1 clinical trial will support accelerated development of candidate vaccine.

  • Emerging diseaseDeveloping a global workforce to tackle emerging pandemic threats

    When a new pandemic threat like this year’s Ebola outbreak emerges, the importance of preventing and limiting disease spread becomes apparent. Well-trained global health professionals play a key role in preventing and responding to emerging zoonotic disease. Under a new 5-year award of up to $50 million, the University of Minnesota and Tufts University will be part of an international partnership of universities to strengthen global workforce development against emerging pandemic threats.

  • EpidemicsPublic health officials work to ensure that the lessons of Ebola are not forgotten

    Hospitals find it difficult to remain fully prepared for disease outbreaks because they rarely occur and preparation and frequent training are expensive. Public health professionals and infectious disease experts are working to ensure that lessons learned and protocols put in place in response to the Ebola outbreak will be used to prevent and respond to future virus and disease outbreaks.

  • Public healthPre-empting flu evolution may make for better vaccines

    Influenza is a notoriously difficult virus against which to vaccinate. There are many different strains circulating — both in human and animal populations — and these strains themselves evolve rapidly. Yet manufacturers, who need to produce around 350 million doses ahead of the annual flu season, must know which strain to put in the vaccine months in advance — during which time the circulating viruses can evolve again. An international team of researchers has shown that it may be possible to improve the effectiveness of the seasonal flu vaccine by “pre-empting” the evolution of the influenza virus.

  • EbolaScientists identify weak spots in Ebola’s defenses

    Scientists have identified weak spots on the surface of Ebola virus that are targeted by the antibodies in ZMapp, the experimental drug cocktail administered to several patients during the recent Ebola outbreak. “The structural images of Ebola virus are like enemy reconnaissance,” said one of the scientists involved in the research. “They tell us exactly where to target antibodies or drugs.”

  • EbolaUsing data to fight Ebola

    The current Ebola outbreak is the largest in recorded history, claiming more victims than all previous twenty major outbreaks combined since Ebola was discovered in 1976. Governments and the private sector are using the latest data technology to process, store, and analyze information and communication records from Ebola-stricken countries to help locate and predict the spread of the disease.